AU722627B2 - Stable particle in liquid formulations - Google Patents

Stable particle in liquid formulations Download PDF

Info

Publication number
AU722627B2
AU722627B2 AU65101/98A AU6510198A AU722627B2 AU 722627 B2 AU722627 B2 AU 722627B2 AU 65101/98 A AU65101/98 A AU 65101/98A AU 6510198 A AU6510198 A AU 6510198A AU 722627 B2 AU722627 B2 AU 722627B2
Authority
AU
Australia
Prior art keywords
formulation according
microparticles
phase
formulation
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU65101/98A
Other languages
English (en)
Other versions
AU6510198A (en
Inventor
Jaap Kampinga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Holdings Cambridge Ltd
Original Assignee
Quadrant Holdings Cambridge Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10809442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU722627(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Holdings Cambridge Ltd filed Critical Quadrant Holdings Cambridge Ltd
Publication of AU6510198A publication Critical patent/AU6510198A/en
Application granted granted Critical
Publication of AU722627B2 publication Critical patent/AU722627B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU65101/98A 1997-03-18 1998-03-18 Stable particle in liquid formulations Ceased AU722627B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9705588.3A GB9705588D0 (en) 1997-03-18 1997-03-18 Stable particle in liquid formulations
GB9705588 1997-03-18
PCT/GB1998/000817 WO1998041188A2 (en) 1997-03-18 1998-03-18 Stable particle in liquid formulations

Publications (2)

Publication Number Publication Date
AU6510198A AU6510198A (en) 1998-10-12
AU722627B2 true AU722627B2 (en) 2000-08-10

Family

ID=10809442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65101/98A Ceased AU722627B2 (en) 1997-03-18 1998-03-18 Stable particle in liquid formulations

Country Status (14)

Country Link
US (1) US6669963B1 (enExample)
EP (1) EP1007000B1 (enExample)
JP (1) JP2002504090A (enExample)
CN (1) CN1256626A (enExample)
AT (1) ATE325605T1 (enExample)
AU (1) AU722627B2 (enExample)
BR (1) BR9808920A (enExample)
CA (1) CA2293682C (enExample)
DE (1) DE69834495T2 (enExample)
EA (1) EA001873B1 (enExample)
GB (1) GB9705588D0 (enExample)
NO (1) NO994508L (enExample)
NZ (1) NZ337666A (enExample)
WO (1) WO1998041188A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008979A1 (en) 1994-09-22 1996-03-28 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
WO1999047174A1 (en) * 1998-03-18 1999-09-23 Cambridge Biostability Limited Amorphous glasses for stabilising sensitive products
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
DE19943491B4 (de) * 1999-09-10 2010-04-01 Südzucker AG Mannheim/Ochsenfurt Verbesserte Komprimate
WO2001037804A2 (en) * 1999-11-22 2001-05-31 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
GB0024271D0 (en) * 2000-09-25 2000-11-15 Colaco Camilo Improved methods and compositions for pulmonary delivery of actives
RU2259817C2 (ru) * 2000-10-13 2005-09-10 Кембридж Байостэбилити Лтд. Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
EP1449523A1 (en) * 2000-10-13 2004-08-25 Cambridge Biostability Ltd Composition and method for stable injectable liquids
PL360052A1 (en) * 2000-10-13 2004-09-06 Cambridge Biostability Ltd. Composition and method for stable injectable liquids
US20020150621A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for drug delivery
US7153472B1 (en) 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
US6623762B2 (en) 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
FR2825276B1 (fr) * 2001-05-31 2004-11-26 Seppic Sa Adujvant d'immunite sous forme solide et vaccin le contenant
EP1418229B1 (en) * 2001-07-02 2009-04-22 Asahi Kasei Pharma Corporation Method of stabilizing alkaline phosphatase
BRPI0211842B1 (pt) * 2001-08-10 2018-04-03 Hayashibara Co., Ltd. Associado cristalino compreendendo trealose e cloreto de cálcio e composição que o compreende
GB2404865B (en) 2001-09-11 2005-09-28 Caretek Medical Ltd Novel drug delivery technology
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
JP4836797B2 (ja) * 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
US20060142630A1 (en) * 2004-12-29 2006-06-29 Attila Meretei Systems and methods for treating a thrombus in a blood vessel
US7515971B1 (en) * 2005-09-09 2009-04-07 Pacesetter, Inc. Left atrial pressure sensor lead
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US8946200B2 (en) 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
DE102006056790B3 (de) * 2006-12-01 2008-01-17 IfP Privates Institut für Produktqualität GmbH Laboreinmalartikel für Analyse und Diagnosik
ATE515554T1 (de) * 2006-12-04 2011-07-15 Merck Patent Gmbh Furochromanderivate
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
MX2010001311A (es) * 2007-07-31 2010-04-21 Otsuka Pharma Co Ltd Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.
CA2716546A1 (en) * 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
US8404850B2 (en) 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8722706B2 (en) 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2011007327A2 (en) * 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
US8293299B2 (en) 2009-09-11 2012-10-23 Kraft Foods Global Brands Llc Containers and methods for dispensing multiple doses of a concentrated liquid, and shelf stable Concentrated liquids
CN102115737B (zh) * 2009-12-31 2015-06-03 深圳迈瑞生物医疗电子股份有限公司 稳定碱性磷酸酶或其标记物的试剂和方法
US9028873B2 (en) 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
CN102269761A (zh) 2010-06-04 2011-12-07 深圳迈瑞生物医疗电子股份有限公司 一种碱性磷酸酶结合物的合成工艺
CN102269762B (zh) 2010-06-04 2014-12-10 深圳迈瑞生物医疗电子股份有限公司 结合物的制备方法及相关试剂盒
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
MX363596B (es) 2011-09-09 2019-03-27 Kraft Foods Group Brands Llc Concentrados para bebidas preparadas por infusión, estables en estante, y métodos de hacerlos.
US20140302021A1 (en) 2011-10-25 2014-10-09 Onclave Therapeutics Limited Antibody formulations and methods
US11013248B2 (en) 2012-05-25 2021-05-25 Kraft Foods Group Brands Llc Shelf stable, concentrated, liquid flavorings and methods of preparing beverages with the concentrated liquid flavorings
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
AU2015284012B2 (en) 2014-07-03 2019-04-18 Kraft Foods Group Brands Llc Low water coffee and tea beverage concentrates and methods for making the same
CN111558046A (zh) * 2020-05-27 2020-08-21 华润昂德生物药业有限公司 海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970765A (en) * 1975-07-03 1976-07-20 General Foods Corporation Method for producing sucrose fixed volatile flavors
US4031255A (en) * 1975-07-03 1977-06-21 General Foods Corporation Fixing acetaldehyde in sucrose
GB1490814A (en) * 1975-07-22 1977-11-02 Cadbury Ltd Heat-resistant chocolate product and method of manufacturing same
JPS562908A (en) * 1979-06-20 1981-01-13 Nikken Kagaku Kk Preparation of stable live bacterial pharmaceutical remedy
EP0140255B1 (en) * 1983-10-14 1991-05-15 Sumitomo Pharmaceuticals Company, Limited Sustained-release injections
WO1989003671A1 (fr) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Preparation a liberation entretenue
US5250429A (en) * 1991-09-20 1993-10-05 Pharmacia P-L Biochemicals Inc. Glassified restriction enzymes
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
JPH10503769A (ja) * 1994-08-04 1998-04-07 クアドラント ホールディングス ケンブリッジ リミテッド 配合されている分子の制御放出用の固形放出系およびその製造方法
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5593824A (en) * 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
CN1245957C (zh) 1995-06-07 2006-03-22 廓德伦特控股剑桥有限公司 将物质稳定掺入干燥泡沫玻璃基质中的方法以及由此制得的组合物
US5958455A (en) 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5766520A (en) 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation

Also Published As

Publication number Publication date
ATE325605T1 (de) 2006-06-15
GB9705588D0 (en) 1997-05-07
EP1007000A2 (en) 2000-06-14
CN1256626A (zh) 2000-06-14
NZ337666A (en) 2001-04-27
US6669963B1 (en) 2003-12-30
DE69834495D1 (de) 2006-06-14
CA2293682C (en) 2007-01-16
AU6510198A (en) 1998-10-12
BR9808920A (pt) 2000-08-01
EA199900835A1 (ru) 2000-04-24
DE69834495T2 (de) 2006-09-07
NO994508D0 (no) 1999-09-17
EA001873B1 (ru) 2001-10-22
NO994508L (no) 1999-11-17
EP1007000B1 (en) 2006-05-10
CA2293682A1 (en) 1998-09-24
WO1998041188A2 (en) 1998-09-24
JP2002504090A (ja) 2002-02-05
WO1998041188A3 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
AU722627B2 (en) Stable particle in liquid formulations
US8703095B2 (en) Immuno-adjuvant emulsion
US7153472B1 (en) Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
CA2565296C (en) Sustained-release microspheres and methods of making and using same
US6190701B1 (en) Composition and method for stable injectable liquids
KR20110007099A (ko) 항원보강제 함유 백신 조성물의 안정화 방법
KR20050011741A (ko) 분무 건조에 의한 생물학적 활성 물질의 보존
US20080152738A1 (en) Formulations useful for immunotherapy for cancers containing bacterial component as an active ingredient
CA2689856C (en) Composition and method for stable injectable liquids
AU2001211986A1 (en) Composition and method for stable injectable liquids
WO2023126053A1 (en) Lipid-based formulations for administration of rna
WO2001037804A2 (en) Preservation and formulation of bioactive materials
AU2022374004A1 (en) Compositions for administration of different doses of rna
AU2005203369B2 (en) Pharmaceutical liquid suspensions
EP1452171B1 (en) Pharmaceutical liquid suspensions
JP4382706B2 (ja) 医薬液体懸濁物
NZ538681A (en) A pharmaceutical composition comprising active biological ingredient carried by particles that form a stable suspension in a liquid indefinitely
NZ525026A (en) A two-component composition comprising particles of sugar glass and a biocompatible liquid perfluorocarbon
WO2012152707A1 (en) Microemulsions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired